Harriette Van Spall
Yesterday at the Heart Failure Association (HFA)’s Heart Failure 2023 Late-Breaking Clinical Trials: Patient Monitoring session, PHRI Scientist Harriette Van Spall presented three-year clinical outcomes of her randomized controlled trial, PACT-HF, looking at patient-centered care transitions in heart failure.
Accounting for death as a competing risk, the trial’s transitional care intervention was associated with: decreased risk of all-cause ED visits in females; decrease risk of HF readmission; and no change in risk of all-cause readmission.
In this video, Van Spall is joined by investigators Jozine ter Maaten and Tariq Ahmad to discuss the latest data on hospital-to-home transition in heart failure, drawing from the late-breaking data presented at HFA 2023 from three studies: PACT-HF, PROMPT-AHF and STRONG-HF Kidney.
“Sex-specific clinical outcomes of the PACT-HF randomized trial” by Van Spall et al was published in Circulation: Heart Failure in late 2021.
That publication won Van Spall the 2022 Dr. Nanette K. Wenger ‘Research Goes Red’ Award presented by the American Heart Association. She received the award, and presented her paper, at AHA Scientific Sessions in Chicago in November 2022.
